or organic anions. Because of the diversity of the cation and anion constituents, Baker et al. (2005) has estimated that up to 10 trillion combinations are theoretically possible. However, the commonly used cations for ILs are based on an imidazolium, pyridinium, or pyrrolidinium moiety with alkyl chain substituents, while the anions include hexafluorophosphate, tetrafluoroborate, nitrate or chloride (Zhao et al., 2007) . Research on ILs has expanded rapidly because of their potential industrial application to replace or reduce the reliance on the classical volatile organic solvents (Baker et al., 2005; Rogers and Seddon, 2003) . ILs have excellent properties that include non-volatility, low melting point, thermal stability, high ionic conductivity, high viscosity, and large electrochemical windows (Endres and Zein El Abedin, 2006) . In addition, depending on the chemical nature of the cation/anion, ILs with specific characteristics can be formulated.
ILs are considered to be "green chemicals" and "environmentally benign" due to their much lower vapor pressure than conventional organic solvents (Earle and Seddon, 2000; Welton, 1999) . However, increased use of these compounds in large-scale industrial applications could lead to environmental contamination through accidental spills, effluents or geologic adsorption. Many ILs could be transported unimpeded through the underground water because of their miscibility with water (Couling et al., 2005) . Ecotoxicological studies have been conducted in a variety of microorganisms including algae, diatoms, water fleas Docherty and Kulpa, 2005; Latala et al., 2005) . In general, these studies demonstrate that toxicity is determined mainly by the cation, not by varying the anion, and that toxicity increases with increasing length of the alkyl chains. In addition, several studies have demonstrated the antimicrobial activity of ILs against various strains of bacteria and fungi (Pernak et al., 2003; Docherty and Kulpa, 2005) . In the few studies that compared the toxicity of imidazolium and pyridinium compounds, neither cation type was consistently more toxic than the other (Bernot et al., 2005 a and b; Docherty and Kulpa, 2005) . However, an enzyme inhibition study showed that purified acetylcholinesterase could be inhibited by imidazolium and pyridinium ionic liquids with EC 50 values as low as 13 µM; greater inhibition of acetylcholinesterase activity was observed with pyridinium cations than with imidazolium cations (Stock et al., 2004) .
Likewise, little disposition, metabolism and/or toxicity information is available on ILs in mammalian systems. Ranke et al. (2004) investigated the toxicity of imidazolium ionic liquids on leukemia and glioma rat cell lines and found these ILs were more toxic than conventional solvents, such as acetone and acetonitrile. One IL, 1-butyl-3-methylimidazolium chloride (Bmim-Cl), has been shown to cause dermal irritation when applied topically to rats, but produced only minimal contact sensitization when evaluated in the mouse local lymph node assay (Landry et al., 2005) . Systemic toxicity was also observed in these animals when Bmim-Cl was applied in a hydrophobic vehicle. In a study by Landry et al. (2005) , the acute single oral dose LD 50 of Bmim-Cl was reported to be 550 mg/kg. Three ILs, Bmim-Cl, NBuPy-Cl and 1-butyl-1-methylpyrrolidinium chloride, were nominated to the National Toxicology Program for toxicological testing, because they are representative of the most common cation classes of ILs and are the starting materials for many other ILs. Disposition and toxicokinetic studies were conducted on these compounds to determine the extent of systemic bioavailability, metabolism, distribution and elimination in rats and mice. We recently reported that systemically available Bmim-Cl was cleared readily from the blood by renal processes and eliminated in the urine as parent compound in rats and mice (Sipes et al., 2008) . Because of the rapid renal clearance and the cationic nature of Bmim-Cl, it was speculated that it may be a substrate for organic cation transporters (OCTs).
The studies reported here were designed to determine if NBuPy-Cl had a toxicokinetic profile similar to Bmim-Cl, and to examine directly if it was a substrate for and/or an inhibitor of
OCT2.
This article has not been copyedited and formatted. The final version may differ from this version. To assess the effect of dose and route on excretion, NBuPy-Cl was administered intravenously (5 mg/kg, 50 µCi/kg) or orally (0.5, 5 or 50 mg/kg, 50 µCi/kg) to male F-344 rats and orally (50 mg/kg, 50 µCi/kg) to female B6C3F1 mice. In the repeat dose study, NBuPy-Cl was administered orally to male F-344 rats 50 mg/kg/day, 50 µCi/kg/day for 1 day or 5 days.
For the dermal application studies, rats were shaved at the dorsal back and a metal trap was adhered to the skin as described by Winter and Sipes (1993) . The dose (5 mg/kg, 100 µCi/kg,
) was applied to the skin within this circumsubscribed area in vehicles of DMF/water (55/45, v/v), ethanol/water (55/45, v/v) or water. For the NBuPy-Cl toxicokinetic studies, JVC rats were dosed once with NBuPy-Cl intravenously (5 mg/kg, 100 µCi/kg) or orally (50 mg/kg, 100 µCi/kg). In another study, NBuPy-Cl (5 mg/kg, 50 µCi/kg) and inulin (0.67 mg/kg, 250 µCi/kg) were co-administered intravenously to JVC rats. Saline was used as the dosing vehicle in all cases except dermal application.
Sample collection and analysis
This article has not been copyedited and formatted. The final version may differ from this version. Samples were collected and analyzed as described by Sipes et al. (2008) . Briefly, animals were placed into Nalgene ® metabolism cages after dosing. Urine and feces were collected up to 48 h (intravenous), 72h (single oral), 96 h (dermal) or 120 h (repeated oral).
After each collection, the cage was rinsed with around 15 ml water. This cage rinse solution was counted independently, but ultimately added to 14 C recovered in the urine. For NBuPy-Cl toxicokinetic studies, 300 µl of blood was collected via the JVC at 7. 5, 15, 30, 60, 90, 180, 270, 360, 720 and 1440 min. For the co-administration of NBuPy-Cl and inulin, 300 µl of blood was collected at 7. 5, 15, 30, 60, 90, 120, 180, 240, 300, 360 and 720 min. Aliquots of blood removed via the JVC were replaced with an equal volume of saline. At the terminus of each study, animals were euthanized by CO 2 inhalation and various tissues were collected.
Aliquots of urine (100-1000 µl) and cage rinse (1000 µl) were counted directly in triplicate using a Beckman liquid scintillation counter (LSC). In addition, the urine samples were diluted with water (1:1) and filtered through a 0.45-µm Whitman nylon syringe filter. The filtrates were then subjected to HPLC analysis to separate parent compound from any metabolites. The HPLC procedure is identical to that reported for Bmim-Cl (Sipes et al., 2008) .
Briefly, the filtrates were applied to a C18 guard column (4.0x3.0 mm) connected to a C18 reverse-phase column (250x4.6 mm). The mobile phase consisted of acidified (0.1 M trifluoroacetic acid) acetonitrile and water at the flow rate of 1 ml/min for 35 min. Eluting peaks were detected by an INUS radiometric detector. In addition, urine samples obtained from rats administered non-radiolabeled NBuPy-Cl were subjected to liquid chromatography-mass spectrometry (LC-MS) to identify the NBuPy-Cl derived peak appearing in the urine. Analytes were ionized using an electrospray ionization source and dried with nitrogen (10 ml/min) at and tissue) were stored in dark for 48 h prior to liquid scintillation counting. In the dermal application study, radioactivity on the skin surface at the dosing site was removed by washing and tape stripping as described in detail by Sipes et al. (2008) . This recovered Radioactivity in saline washes, plasma and plasma proteins was counted directly by LSC. The washed blood cells were solubilized and counted as described in the sample analysis section.
In vitro transport studies
To determine the transport of TEA or NBuPy-Cl by human organic cation transporter 2 temperature. To initiate the reaction, TEA and/or NBuPy-Cl were added to the cells in 0.4 ml of WB. After 30s, the incubation solution was removed, and the cells were rinsed three times with 1 ml ice cold WB. The cells were then solubilized for 30 min by adding 0.4 ml of NaOH (0.5 M) with 1% SDS. After neutralization by addition of HCL (0.2 ml, 1 M), 0.5 ml of the resulting cell lysate solution was counted by the LSC.
Data analyses
Data are presented as percent of dose recovered or as nmol/g, nmol/ml and ng/ml.
The latter were determined by the specific activity of appropriate dosing solution (dpm/nmol or dpm/ng). where J mapp is the J max for TEA transport times the ratio of K i /K t ; and IC 50 is equal to (Groves et al., 1994) .
Equation 1
Equation 2 This article has not been copyedited and formatted. The final version may differ from this version. 
Results

Disposition studies Intravenous administration
Following a single i.v. dose (5 mg/kg), NBuPy-Cl was rapidly excreted in the urine of male F-344 rats (Figure 2-A) . Greater than 80% of the administered radioactivity was recovered from the urine by 12 h. By 48 h, 97% of the dose was recovered in urine (93%) and feces (4%). Radioactivity detected in the blood samples at 48 h was negligible.
Oral administration
To determine the effect of dose on the disposition of NBuPy-Cl, a single bolus dose providing 0.5, 5 or 50 mg/kg of NBuPy-Cl was administered to male F-344 rats by oral gavage.
NBuPy-Cl (50 mg/kg) was well absorbed and eliminated rapidly from the body (Figure 2 -B).
Dose did not affect the rate or route of excretion of 14 C equivalents (Table 1) . For those three doses, 83-88% of the administered radioactivity was recovered within 24 h with 55-66% in urine and 20-25% in feces. By 72 h, 87-93% of the dose was excreted from the body, of which 62-68% was in the urine. The total 14 C remaining in the liver, kidneys and lung at 72 h was less than 0.01% of dose in the animals administered with 50 mg/kg of NBuPy-Cl.
NBuPy-Cl (50 mg/kg) was orally administered to female B6C3F1 mice to characterize the disposition of NBuPy-Cl in a different species. At 96 h, 82% of the dosed NBuPy-Cl was found in the urine (72%) and feces (10%) as shown in table 1. The urinary elimination profile was similar to that observed in rats, but the fecal recovery was lower (Figure 2 
-C). No urine
This article has not been copyedited and formatted. The final version may differ from this version. Following daily oral administration of NBuPy-Cl (50 mg/kg/day) for 5 days, the elimination profile of NBuPy-Cl was not altered in male F-344 rats (Figure 3) . Essentially, 93-99% of each dose was eliminated within 24 h after its administration, with 51-59% appearing in the urine. At 24 h after the 5 th dose, 97% of the total administered dose had been excreted (Table 2) . At this time analyzed tissues contained less than 1% of the total dose.
Concentration of [
14 C]NBuPy-Cl equivalents in tissues ranged from 1.5 to 21 nmol/g (Table 3 ). This pattern was also observed in urine samples collected at later time points (24, 36, 48, and 72 h). Several minor peaks noted only in 6 h urine samples of rats were also observed in the dosing solution. The only exception was the new, small peak at retention time of 12 min.
However, it accounted for less than 1% of the total [ Table 4 . After oral administration, NBuPy-Cl (50 mg/kg) was absorbed into the systemic blood and reached its maximum concentration (2.6 µg/ml) at 1.3 h.
The oral systemic bioavailability at 6 h was determined to be 47%, based on AUC oral /AUC i.v.
This article has not been copyedited and formatted. The final version may differ from this version. and adjusted for dose (Shargel and Yu, 1993) . Radio-HPLC analysis of the blood extracts following both i.v. and oral administration showed only one peak, which co-eluted with between NBuPy-Cl and inulin, but NBuPy-Cl is distributed more widely than that of inulin by 6 fold ( Table 4 ). The systemic clearance of NBuPy-Cl exceeded that of inulin by 3 fold.
hOCT2-mediated TEA and NBuPy-Cl transport
This article has not been copyedited and formatted. The final version may differ from this version. 
Discussion
ILs are being increasingly examined in industrial and laboratory chemical processes such as synthesis, catalysis and enzymatic biocatalysis, electrolysis, and extraction. ILs are also expected to be applied in consumer products including batteries, photoelectrochemical devices, fuel cells for automotive consumption and surgical implants (Freemantle, 2000) .
Therefore, the potential for exposure will increase with increased use of ILs. Because of the low volatility of these agents, exposure would most likely occur orally and/or dermally. Thus, it is important to understand how ILs are absorbed and cleared from the systemic circulation. In a recent paper we reported that in rodents the IL, Bmim-Cl, was partially absorbed after oral or dermal administration, but readily eliminated as parent compound in the urine. The studies here examine the absorption and tissue retension of another IL, NBuPy-Cl, and provide evidence for an important role of OCT2 in its urinary elimination.
NBuPy-Cl was absorbed from the gastrointestinal tract following oral administration. The oral systemic bioavailability of NBuPy-Cl (50 mg/kg) in rats was calculated to be 47% at 6 h, based on the blood AUC oral /AUC i.v. . This is in good agreement with the amount of radiolabel excreted in the urine of rats in 6 h (47±2% of dose, Figure 2 -B). However, the overall bioavailability is greater than this based on the urinary excretion (67% of dose) over 72 h.
Blood at times after 6 h could not be used to determine the oral AUC, as they had 14 C levels that were above the limit of detection, but below the limit of quantification. This extra 20% most likely represents additional NBuPy-Cl absorption from intestine, as well as dose that had distributed to the tissues. Because only a small amount of radiolabel appeared in the feces after i.v. administration of NBuPy-Cl (<5% of dose), it can be concluded that the 22-26% of the dose excreted in the feces after oral administration represents unabsorbed compound.
This article has not been copyedited and formatted. The final version may differ from this version. Similar results were observed for urinary elimination of NBuPy-Cl administered orally to female mice. Fecal excretion was lower in mice, but this may be due to poor recovery of fecal materials (Sipes et al., 2008) .
Over the dose range studied, the magnitude of a single dose did not affect the rate or route of NBuPy-Cl excretion. Repeated daily dosing also had a minimal, if any, effect on the elimination. It appears that nearly the entire daily dose was eliminated within each 24 h interval as the parent compound. At 24 h after the 5th dose, the concentration of NBuPy-Cl increased 2-4 fold in most tissues, which reflects, in part, the higher NBuPy-Cl concentration in the blood. However, this does not have a significant influence on the disposition of NBuPyCl, because the total radioactivity recovered in all tissues represents approximately 1% of the administered dose. In the particular group of rats used in the repeated dose study, fecal excretion was about 20% higher than the other studies (Table 1 and Table 2 ). This occurred in the animals receiving one dose as well as those receiving five doses. Since these animals
were not fasted, the presence of food most likely reduced absorption. NBuPy-Cl remodeling the barrier function of the skin, because irritation (redness and slight edema) was observed at the dosing site when a higher dose of NBuPy-Cl (50 mg/kg, 1250
) was applied in water and ethanol vehicle (data not shown).
As observed with Bmim-Cl, no evidence of metabolism was noted for the systemically available NBuPy-Cl. As stated above, NBuPy-Cl was eliminated primarily in the urine as the parent compound in both rats and mice, independent of dose and route of administration.
Also, only NBuPy-Cl was detected in the blood following i.v. or oral administration. The small peak that appeared in the urine (retention time of 12 min) might be a metabolite of a contaminant present in the dosing solution. It was only observed in the 6 h urine samples and accounted for less than 1% of the total dose. OCTs transport various physiological, pharmacological and toxic chemicals, like dopamine, metformin and nicotine, respectively (Wright, 2005) . Therefore, impeded function of OCTs could alter the blood levels of these chemicals. It has been reported that TEA clearance was significantly decreased in the OCT1 and OCT2 double knockout mice and in the rats with lower OCT1 and OCT2 expression (Jonker et al., 2003; Matsuzki et al., 2008) .
Absence of OCT2 has little effect on the pharmacokinetics of TEA in mice since both OCT1
and OCT2 are richly expressed in the mouse kidney, but OCT1 is weakly expressed in human kidney (Jonker et al., 2003; Motohashi et al., 2002) . Therefore, because of its potent inhibition of hOCT2, impaired absorption and renal secretion of some cationic drugs might occur in human exposed to NBuPy-Cl.
In summary, NBuPy-Cl was readily absorbed from the rodent gastrointestinal tract and then widely distributed in the body. Its dermal absorption depended on the vehicle applied.
This article has not been copyedited and formatted. The final version may differ from this version. NBuPy-Cl was excreted primarily in the urine as the parent compound independent of dose and route of administration in both rats and mice. Its rapid renal elimination is mediated, in part, by organic cation transporter 2.
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